Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Adipose-derived relaxing factor (ADRF) from perivascular adipose tissue acts as a potassium channel opener, offering a potential therapeutic target for vascular dysfunction in metabolic and cardiovascular diseases.
Perivascular adipose tissue has been recognized unequivocally as a major player in the pathology of metabolic and cardiovascular diseases. Through its production of adipokines and the release of other thus far unidentified factors, this recently discovered adipose tissue modulates vascular regulation and the myogenic response. After the discovery of its ability to diminish the vessel's response to vasoconstrictors, a new paradigm established adipose-derived relaxing factor (ADRF) as a paracrine smooth muscle cells' potassium channel opener that could potentially help combat vascular dysfunction. This review will discuss the role of ADRF in vascular dysfunction in obesity and hypertension, the different potassium channels that can be activated by this factor, and describes new pharmacological tools that can mimic the ADRF effect and thus can be beneficial against vascular dysfunction in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Tano et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: